SeekingAlpha · Aug 25, 2026
Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma
Immatics is downgraded to Buy due to partial partnership termination and pivotal trial dependency. Click to learn more.
IM
NASDAQ · IMTX
Immatics N.V.
Healthcare · Biotechnology
$8.60
Up+$0.04 (+0.47%)
Updated Sep 17, 2026, 12:09 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.22B
- P/E ratio
- -8.99
- Dividend yield
- 0.00%
- 52-week range
- $5.92 – $12.41
- Volume
- 355.79K
- Avg. volume
- 800.14K
Price performance
IMTX price history
1M range · 19 trading sessions · Daily adjusted prices
IMTX closed at $8.60 after 19 trading sessions, down 7.03% for the selected period.
- Last close
- $8.60
- Period change
- -7.03%
- Period low
- $8.55
- Period high
- $9.56
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $8.59 | $8.77 | $8.335 | $8.60 | 355.79K |
| Sep 14, 2026 | $8.80 | $8.806 | $8.59 | $8.62 | 378.59K |
| Sep 11, 2026 | $8.84 | $8.921 | $8.535 | $8.79 | 527.25K |
| Sep 10, 2026 | $9.02 | $9.09 | $8.655 | $8.75 | 798.77K |
| Sep 9, 2026 | $9.38 | $9.555 | $9.085 | $9.11 | 326.08K |
| Sep 8, 2026 | $9.37 | $9.515 | $9.31 | $9.44 | 699.52K |
| Sep 4, 2026 | $9.34 | $9.57 | $9.30 | $9.56 | 497.16K |
| Sep 3, 2026 | $9.53 | $9.69 | $9.26 | $9.46 | 494.34K |
| Sep 2, 2026 | $9.47 | $9.7234 | $9.295 | $9.50 | 761.07K |
| Sep 1, 2026 | $9.38 | $9.60 | $9.23 | $9.43 | 607.12K |
| Aug 31, 2026 | $9.36 | $9.55 | $9.2309 | $9.53 | 725.25K |
| Aug 28, 2026 | $9.68 | $9.89 | $9.32 | $9.45 | 1.09M |
| Aug 27, 2026 | $9.36 | $9.48 | $9.1766 | $9.36 | 743.42K |
| Aug 26, 2026 | $9.22 | $9.465 | $8.97 | $9.43 | 777.96K |
| Aug 25, 2026 | $9.59 | $9.75 | $9.04 | $9.24 | 1.06M |
| Aug 24, 2026 | $8.86 | $8.905 | $8.56 | $8.69 | 338.15K |
| Aug 21, 2026 | $8.60 | $9.0499 | $8.60 | $8.93 | 611.32K |
| Aug 20, 2026 | $9.12 | $9.13 | $8.40 | $8.55 | 474.77K |
| Aug 19, 2026 | $9.28 | $9.31 | $9.02 | $9.25 | 593.32K |
Latest IMTX news
The latest Smart Investors Daily articles mentioning IMTX.
Stock researchCompany · Overview
IMTX research
Overview
Company profile and research snapshot.
Company profile
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $17.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2026 | Chardan Capital | Buy | — |
| Apr 28, 2026 | TD Cowen | Buy | — |
| Nov 24, 2025 | Chardan Capital | Buy | — |
| Nov 19, 2025 | Mizuho | Outperform | — |
| Nov 18, 2025 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 25, 2026
Immatics Announces $150M Underwritten Offering Of Ordinary Shares And Pre-Funded Warrants
Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company"))), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced
Benzinga · Aug 18, 2026
Immatics Q2 EPS $(0.53) Misses $(0.43) Estimate, Sales $10.630M Miss $14.590M Estimate
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.43) by 23.26 percent. This is a 19.7 percent increase over losses of $(0.66) per share from the
SeekingAlpha · Jun 16, 2026
Immatics: PRAME Is Becoming More Than A Single-Asset Story
Immatics is evolving into a PRAME-focused oncology platform with three monetization paths. Read why I am bullish on IMTX stock.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
